Aflac (NYSE:AFL) Price Target Raised to $93.00

Aflac (NYSE:AFL) had its price objective lifted by Citigroup from $84.00 to $93.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the financial services provider’s stock. Citigroup’s target price points to a potential downside of 1.57% from the company’s current price.

Other equities analysts also recently issued research reports about the company. Bank of America boosted their target price on Aflac from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Jefferies Financial Group reduced their price target on shares of Aflac from $84.00 to $83.00 and set a “hold” rating for the company in a research report on Friday, June 28th. Keefe, Bruyette & Woods raised their price objective on shares of Aflac from $83.00 to $87.00 and gave the stock a “market perform” rating in a report on Wednesday, April 10th. Wells Fargo & Company boosted their target price on shares of Aflac from $81.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, May 10th. Finally, Morgan Stanley raised their price target on shares of Aflac from $80.00 to $84.00 and gave the stock an “equal weight” rating in a research note on Monday, April 15th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Aflac presently has a consensus rating of “Hold” and a consensus price target of $86.46.

Aflac Stock Down 0.0 %

NYSE AFL traded down $0.02 during mid-day trading on Tuesday, hitting $94.48. The company’s stock had a trading volume of 90,868 shares, compared to its average volume of 2,201,471. The company has a current ratio of 0.08, a quick ratio of 0.08 and a debt-to-equity ratio of 0.34. The company’s 50 day simple moving average is $89.24 and its 200 day simple moving average is $84.89. The firm has a market capitalization of $53.69 billion, a price-to-earnings ratio of 10.43, a PEG ratio of 2.54 and a beta of 0.95. Aflac has a twelve month low of $71.97 and a twelve month high of $95.49.

Aflac (NYSE:AFL) last released its quarterly earnings results on Monday, May 6th. The financial services provider reported $1.66 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.08. Aflac had a return on equity of 16.88% and a net margin of 27.67%. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $4.09 billion. During the same period in the prior year, the firm posted $1.55 EPS. Aflac’s quarterly revenue was up 13.3% compared to the same quarter last year. Analysts anticipate that Aflac will post 6.44 earnings per share for the current year.

Insider Activity at Aflac

In other Aflac news, Director Charles D. Lake II sold 22,378 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $87.47, for a total value of $1,957,403.66. Following the completion of the transaction, the director now owns 61,522 shares in the company, valued at approximately $5,381,329.34. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Aflac news, Director Charles D. Lake II sold 22,378 shares of the stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $87.47, for a total value of $1,957,403.66. Following the sale, the director now directly owns 61,522 shares in the company, valued at approximately $5,381,329.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph L. Moskowitz sold 600 shares of the firm’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $84.84, for a total transaction of $50,904.00. Following the completion of the transaction, the director now directly owns 27,550 shares of the company’s stock, valued at $2,337,342. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aflac

A number of institutional investors and hedge funds have recently bought and sold shares of AFL. TriaGen Wealth Management LLC grew its holdings in shares of Aflac by 3.6% during the 2nd quarter. TriaGen Wealth Management LLC now owns 3,377 shares of the financial services provider’s stock valued at $302,000 after purchasing an additional 117 shares during the last quarter. Jaffetilchin Investment Partners LLC grew its position in shares of Aflac by 1.7% in the 1st quarter. Jaffetilchin Investment Partners LLC now owns 7,254 shares of the financial services provider’s stock worth $623,000 after buying an additional 121 shares during the last quarter. Burns Matteson Capital Management LLC increased its stake in shares of Aflac by 4.1% during the second quarter. Burns Matteson Capital Management LLC now owns 3,077 shares of the financial services provider’s stock valued at $275,000 after buying an additional 121 shares during the period. Flputnam Investment Management Co. raised its holdings in shares of Aflac by 0.5% during the fourth quarter. Flputnam Investment Management Co. now owns 25,031 shares of the financial services provider’s stock valued at $2,065,000 after acquiring an additional 122 shares in the last quarter. Finally, ICA Group Wealth Management LLC lifted its stake in Aflac by 4.3% in the fourth quarter. ICA Group Wealth Management LLC now owns 2,974 shares of the financial services provider’s stock worth $245,000 after acquiring an additional 122 shares during the period. 67.44% of the stock is owned by hedge funds and other institutional investors.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.